Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

The preclinical pharmacodynamic and pharmacokinetic properties of 4‐methylbenzyl (3S, 4R)‐3‐fluoro‐4‐[(Pyrimidin‐2‐ylamino) methyl] piperidine‐1‐carboxylate (CERC‐301), an orally bioavailable selective N‐methyl‐D‐aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist, were characterized to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Garner, Rachel, Gopalakrishnan, Shobha, McCauley, John A., Bednar, Rodney A., Gaul, Stanley L., Mosser, Scott D., Kiss, Laszlo, Lynch, Joseph J., Patel, Shil, Fandozzi, Christine, Lagrutta, Armando, Briscoe, Richard, Liverton, Nigel J., Paterson, Blake M., Vornov, James J., Mazhari, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777252/
https://www.ncbi.nlm.nih.gov/pubmed/27022470
http://dx.doi.org/10.1002/prp2.198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777252/
https://www.ncbi.nlm.nih.gov/pubmed/27022470
http://dx.doi.org/10.1002/prp2.198

Ejemplares similares